| Name | Title | Contact Details |
|---|
Synspira Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis (CF) and other rare diseases.
BioHitech America is the industry leader in the development of a simple, cost-effective food waste disposal technology designed to solve today’s landfill diversion and sustainability objectives. The Eco-Safe Digester handles food waste at the point of generation, no residual food waste to store or transport. The Eco-Safe Digester can convert up to 2,400 pounds of food waster per day into a nutrient-neutral grey water that can safely be disposed of via municipal sewer systems. The Eco-Safe Digester saves money by avoiding disposal costs and significantly reduces greenhouse gas emissions by providing a sustainable means of transportation for the waste by-product with doesn’t require on-road transportation. The Eco-Safe Digester’s cloud-based management solution is designed to measure and collect food waste data. It correlates information to report cost savings and environmental reductions as well as communicate opportunities to prevent waste altogether. This modifiable data can also be used to assess the performance of your staff and predict trends for smarter budgeting and purchasing purposes. In addition to diverting food waste from landfills and converting food waste into a resource, the machine is now poised for significant growth in this emerging data-driven zero waste initiative climate because it identifies waste in order to prevent the creation of it all together. Already implemented in many applications across the globe, the Eco-Safe Digester is ideal for use in any food service, hospitality, healthcare, government, conference center, education center, or stadium that generates a high volume of waste.
Novan, Inc. is a clinical-stage biotechnology company focused on leveraging nitric oxide`s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. We believe that our ability to conveniently deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to significantly improve patient outcomes in a variety of diseases.
Geneos is developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells.
Celgene Corporation is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Our talent, scientific knowledge and research capabilities help us to deliver access to innovative, disease-altering therapies to those who need them most. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies. Celgene is headquartered in Summit, New Jersey, and employs more than 7,000 people located in more than 60 countries.